Search For "bbv152"
Covaxin booster dose increases immune response by 40 times, gives long-ter
Updated : 3 years, 10 months ago IST
Hyderabad (Telangana) [India], July 20 (ANI): Hyderabad-based Bharat Biotech on Wednesday announced that the administration of the third dose of its COVID-19 vaccine Covaxin (BBV152) after six months of two-dose vaccination dramatically increased neutralizing antibody responses against both
Read More
Covaxin safe for children aged 2-18 years, says Bharat Biotech
Updated : 3 years, 11 months ago IST
Hyderabad (Telangana) [India], June 17 (ANI): Bharat Biotech International Limited (BBIL) on Thursday announced that Covaxin, its whole-virion inactivated COVID-19 vaccine has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study, said a press
Read More
FDA removes hold on clinical trial for phase 2,3 for COVAXIN-BBV152 says
Updated : 4 years ago IST
Malvern (Pennsylvania) [US], May 23 (ANI): Biotechnology company Ocugen on Monday announced that the US Food and Drug Administration (FDA) lifted the clinical hold on the Company's Phase 2, 3 clinical trials for COVAXIN™ (BBV152).
Read More
Covaxin found to be safe, immunogenic in 2-18 age group in phase 2, 3 stud
Updated : 4 years, 4 months ago IST
Hyderabad (Telangana) [India], December 30 (ANI): Hyderabad based vaccine manufacturer Bharat Biotech on Thursday announced that Covaxin (BBV152) has been found to be "safe, well-tolerated, and immunogenic" in the age group of 2-18 years in phase II/III study, said a company's statement.
Read More
Lancet Infectious Diseases study compare well with phase 3 clinical trials
Updated : 4 years, 6 months ago IST
New Delhi [India], November 25 (ANI): Commenting on the study of the Lancet Infectious Diseases on the effectiveness of COVAXIN (BBV152) against symptomatic RT-PCR, the Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obt
Read More
Covaxin 50 pc effective against symptomatic COVID: Lancet study
Updated : 4 years, 6 months ago IST
New Delhi [India], November 24 (ANI): Two doses of COVID-19 vaccine Covaxin (BBV152) are 50 per cent effective against symptomatic COVID-19 disease, according to the first real-world assessment of the COVID-19 vaccine published in the Lancet Infectious Diseases journal.
Read More
No serious adverse effect due to the COVAXIN vaccine reveals interim findi
Updated : 5 years, 5 months ago IST
New Delhi [India], December 16 (ANI): No serious adverse effect related to the vaccine has been reported by COVID-19 vaccine (BBV152) COVAXIN, the interim finding from the phase 1 clinical trial of COVAXIN has stated which has now been published in the pre-print version on Monday.
Read More